Results 151 to 160 of about 101,286 (277)

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, EarlyView.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. [PDF]

J Clin Oncol
Morris VK, Ciombor KK, Xiao L, Ochieng JK, Marmonti E, Polite B, Weinberg BA, Krauss JC, Hays J, Mukherjee S, Aranha O, Iqbal S, Shields T, Benson AB, Kazmi S, Lieu C, Hochster H, Whisenant J, Haymaker C, Eng C.   +19 more
europepmc   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source

Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis. [PDF]

Nat Cancer
Provencio M, Awad MM, Spicer JD, Janssens A, Moiseyenko F, Gao Y, Watanabe Y, Alexandru A, Guisier F, Frost N, Franke F, Hiltermann TJN, He J, Tanaka F, Lu S, Coronado Erdmann C, Sathyanarayana P, Tran P, Devas V, Cascone T.   +19 more
europepmc   +1 more source

Perioperative Nivolumab in Resectable Non‐Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T

Cancer Science, EarlyView.
ABSTRACT In the randomized phase III CheckMate 77T study, perioperative nivolumab showed statistically significant and clinically meaningful improvement in event‐free survival (EFS) vs. placebo in patients with resectable, non‐metastatic non‐small cell lung cancer (NSCLC).
Fumihiro Tanaka, Yasutaka Watanabe, Shunichi Sugawara, Jiro Okami, Satoshi Muto, Morihito Okada, Yoshitsugu Horio, Masahiro Tsuboi, Yuki Sato, Kazuya Takamochi, Hidehito Horinouchi, Yuichi Tambo, Masahiro Seike, Kyoichi Okishio, Cinthya Coronado Erdmann, Padma Sathyanarayana, Stephanie Meadows‐Shropshire, Hiroyuki Ito   +17 more
wiley   +1 more source

Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma. [PDF]

Front Immunol
Ajani JA, Smyth E, Tougeron D, Jung HA, Tang W, Steenkamp J, Prentiss E, Coaquira Castro J, Szafranski K, Zhan L.   +9 more
europepmc   +1 more source

Decoding Senescence‐Driven Heterogeneity in Early‐Onset Colorectal Cancer for Prognostic and Therapeutic Stratification

Cancer Science, EarlyView.
We uncovered pronounced and heterogeneous tumor senescence in EOCRC, independent of age. By integrating multi‐omics and single‐cell analyses, we developed EO‐Senscore, a prognostic tool that stratifies patients by immune phenotype and therapy response, enabling precision treatment using immunotherapy or senolytic agents. ABSTRACT Early‐onset colorectal
Du Cai, Mingru Mai, Rende Huang, Haoning Qi, Xingzhi Feng, Qianling Gao, Yinmeng Zhang, Chenghang Li, Xiaojian Wu, Yize Mao, Zihuan Yang, Feng Gao   +11 more
wiley   +1 more source

Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma. [PDF]

J Immunother Cancer
Viray H, M Mantia C, Jegede OA, Atkins MB, Rosenblatt L, Choueiri TK, McDermott DF, Regan MM.   +7 more
europepmc   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, EarlyView.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source

Four‐Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI‐52

Cancer Science, EarlyView.
This follow‐up study for TASUKI‐52 trial demonstrates the 4‐year beneficial efficacy of nivolumab (NIV) combined with chemotherapy (CP) and bevacizumab (BEV) in patients with nonsquamous non‐small cell lung cancer (NSCLC) and reveals potential patient backgrounds associated with long‐term survival.
Jong‐Seok Lee, Shunichi Sugawara, Jin‐Hyoung Kang, Hye Ryun Kim, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Takako Inoue, Makoto Nishio, Yasushi Goto, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa   +18 more
wiley   +1 more source